Decitabine Induces Subtype-Specific Epigenomic Remodeling and Perturbs Age-Associated Regulatory CpGs in Breast Cancer
Cancer Informatics · 2026-05 · 25
DOI: 10.1177/11769351261452670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Informatics, online erschienen am 26.05.2026. Verfasst von Areez Shafqat und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alfaisal University.
Abstract (Originalsprache)
Objectives
Breast cancer (BC) subtypes such as HR+, HER2+, and triple-negative (TNBC) show distinct molecular features, treatment responses, and outcomes. DNA methylation is a key, targetable epigenetic regulator in BC. This study examined whether the DNA methyltransferase inhibitor decitabine (DAC) produces subtype-specific epigenomic and transcriptional effects in breast cancer cell lines representing distinct molecular subtypes.
Methods
Gene expression and DNA methylation data from DAC-treated and untreated T-47D (Luminal-A) and JIMT-1 (HER2-amplified, trastuzumab-resistant with a TNBC-like phenotype) breast cancer cell lines were obtained from a published dataset. Differential expressions were assessed using limma , and methylation changes were defined using β-value thresholds. Integrated epigenomic–transcriptional analysis, functional enrichment, Horvath clock CpG evaluation, and survival analysis were performed in the METABRIC and TCGA cohorts.
Results
In JIMT-1, DAC caused hypomethylation at 1195 CpG sites and upregulation of 187 genes, including TFAP2E , an age-associated locus selectively hypomethylated after DAC. In T-47D, DAC induced hypomethylation at 1937 CpGs and upregulated 248 genes. Amongst these, KRT20 was upregulated despite promoter hypermethylation, indicating a subtype-specific regulatory architecture. DAC-responsive genes in JIMT-1 were enriched for cytokine signaling and piRNA-mediated epigenetic silencing, whereas T-47D showed enrichment for extracellular matrix organization, collagen dynamics, and piRNA processing pathways. Horvath clock CpG analysis showed selective perturbation of age-associated sites. Survival analysis identified 114 DAC-responsive genes associated with overall survival in ER/PR-positive BC and 8 in the JIMT-1-derived gene set.
Conclusion
DAC induces subtype-dependent epigenomic and transcriptional remodeling, selectively disrupts age-associated regulatory programs, and underscores the need for subtype-stratified evaluation of epigenetic therapies in breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
- Biotechnology Center, Khalifa University, Abu Dhabi, UAE.
- Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
- Department of Biological Sciences, University of Jeddah, Saudi Arabia.
ORCID-Profile: Safiah Aldubaisi, Ahmed Yaqinuddin
Förderung
- Alfaisal University
Zitieren
APA
Shafqat, A., Arora, I., Akbar, A., Alfuwais, M., Aldubaisi, S., Khan, M. I., Abu-Zaid, A., Ahmed, F., & Yaqinuddin, A. (2026). Decitabine Induces Subtype-Specific Epigenomic Remodeling and Perturbs Age-Associated Regulatory CpGs in Breast Cancer. Cancer Informatics, 25. https://doi.org/10.1177/11769351261452670
Vancouver
Shafqat A, Arora I, Akbar A, Alfuwais M, Aldubaisi S, Khan MI, et al. Decitabine Induces Subtype-Specific Epigenomic Remodeling and Perturbs Age-Associated Regulatory CpGs in Breast Cancer. Cancer Informatics. 2026;25. doi:10.1177/11769351261452670
BibTeX
@article{Shafqat2026,
author = {Shafqat, Areez and Arora, Itika and Akbar, Arshiya and Alfuwais, Mohammed and Aldubaisi, Safiah and Khan, Mohammad Imran and Abu-Zaid, Ahmed and Ahmed, Firoz and Yaqinuddin, Ahmed},
title = {Decitabine Induces Subtype-Specific Epigenomic Remodeling and Perturbs Age-Associated Regulatory CpGs in Breast Cancer},
journal = {Cancer Informatics},
year = {2026},
volume = {25},
doi = {10.1177/11769351261452670}
}
EUVIMED